GLP-1 Analog Use is Associated With Improved Disease Course in Inflammatory Bowel Disease: A Report from the Epi-IIRN - Takeaways - MDSpire

GLP-1 Analog Use is Associated With Improved Disease Course in Inflammatory Bowel Disease: A Report from the Epi-IIRN

  • By

  • Yuri Gorelik

  • Itai Ghersin

  • Rona Lujan

  • Dima Shlon

  • Yiska Loewenberg Weisband

  • Amir Ben-Tov

  • Eran Matz

  • Galia Zacay

  • Iris Dotan

  • Dan Turner

  • Haggai Bar-Yoseph

  • October 23, 2024

  • 0 min

Share

  • 1

    GLP-1 analogs are associated with improved outcomes in inflammatory bowel disease (IBD) patients with type 2 diabetes mellitus (DM2).

  • 2

    In a cohort of 3737 IBD patients, GLP-1 analog use correlated with a reduced risk of poor disease outcomes, with an adjusted hazard ratio of 0.74.

  • 3

    The protective effect of GLP-1 analogs was particularly significant in obese patients, showing an adjusted hazard ratio of 0.61.

  • 4

    The study found that GLP-1 analogs reduced hospitalization rates among IBD patients, with an adjusted hazard ratio of 0.74.

  • 5

    Further research is needed to explore the mechanisms behind GLP-1 analog effects in IBD and their role in non-DM2 patients.

Original Source(s)

GLP-1 Analog Use is Associated With Improved Disease Course in Inflammatory Bowel Disease: A Report from the Epi-IIRN

  • by Yuri Gorelik, Itai Ghersin, Rona Lujan, Dima Shlon, Yiska Loewenberg Weisband, Amir Ben-Tov, Eran Matz, Galia Zacay, Iris Dotan, Dan Turner, Haggai Bar-Yoseph

  • October 23, 2024

Related Content

Commentary: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo

Insulin-like growth factor binding proteins in metabolic dysfunction-associated steatotic liver disease

Microbiota metabolite butyrate alleviates intestinal inflammation associated with enhanced autophagy-related signaling in DSS-induced colitis